non glp 1 Oral Peptide Receptor Agonists Market Size, Scope and Trends 2026 to 2035 resveratrol. Peptidyl and Non-Peptidyl Oral Glucagon-Like

A country still grappling with undernutrition is now experiencing a sharp rise in obesity alongside economic growth, owing to carb-heavy diets, a shift toward processed foods, sedentary lifestyles and environmental factors

It is estimated to affect 112 million people worldwide by 2040 (Tham et al., 2014)

Studies show weight loss is maintained at 2+ years with continued treatment

*Correspondence: Sharmistha Dey, [email protected] ORCID: Sharmistha Dey, orcid.org/0000-0003-4122-7415 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Fat dissolving injections, often using a substance like deoxycholic acid work by breaking down fat cell membranes